EndoArt SA

EndoArt SA

EndoArt SA

Overview
Date Founded

1998

Headquarters

PSE B,Ecublens, Vaud 1024

Type of Company

Private

Industries

Medical Products & Equipment
Hospitals & Patient Services

Company Description

EndoArt SA develops medical devices and implants. The company was founded in June 1998 by Nikolaos Stergiopulos and is headquartered in Ecublens, Switzerland.

Executives & Employees

Research Director

Paths to EndoArt SA
Potential Connections via
Relationship Science
You
EndoArt SA
Recent Transactions
Details Hidden

Allergan, Inc. purchases EndoArt SA

Investors
Details Hidden

Chief Executive Officer & Director at Rheon Medical SA

Details Hidden

Partner Capital invests in UK and EU based technology companies with strong IP, global potential and the prospect of delivering high returns. The firm invests in broad range of sectors and industries. It provides financing for buyout capital requirements.

Details Hidden

EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany.Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions.EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by EndoArt SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of EndoArt SA's profile does not indicate a business or promotional relationship of any kind between RelSci and EndoArt SA.